Voglibose
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
JSmol) | |
SMILES
| |
| |
| (verify) | |
Voglibose (
diabetes mellitus.[3]
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.[2]
There are three major drugs which belong to this class, acarbose, miglitol and voglibose,[2] of which voglibose is the newest.
Efficacy
A Cochrane systematic review assessed the effect of alpha-glucosidase inhibitors in people with impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin A1c (HbA1c).[4] It was found that there was no conclusive evidence that voglibose compared to diet and exercise or placebo reduced incidence of diabetes mellitus type 2, improved all-cause mortality, reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal stroke, congestive heart failure, or non-fatal myocardial infarction.[4]
References
- PMID 16457643.
- ^ PMID 24551718.
- ^ "Voglibose". AdisInsight. Springer Nature Switzerland AG.
- ^ PMID 30592787.
Further reading
- Miller CK (2004). "New therapeutic options in the treatment of diabetes mellitus". In Greenstein B (ed.). Clinical Pharmacology for nurses (17th ed.). Elsevier Limited, Churchill Livingstone.
- Wilson L (1997). Mehra IV (ed.). Managing the Patient with Type II Diabetes. ISBN 978-0-8342-1018-9.